论文部分内容阅读
食管癌放射治疗的5年生存率为5％～10％。作者从1980～1992年对不能手术切除的81例食管癌采用放射疗法。自1986年起,对其中37例采用白金制剂与放射同时进行治疗。给药方法是:9例采用顺铂(CDDP)静脉给药(50mg,每周一次,总量200mg);11例采用碳铂(CBDCA)静脉给药(100～150mg,每周一次,总量400～900mg);17例采用顺铂动脉灌注(100mg,间隔3～4周,总量100～300mg)。作者对白金制剂并用放射治疗组(并用组)37例与放射线单独治疗组(照射组)44例进行回顾性研究。并用组年龄较照射组年轻(平均年龄:照射组72岁,并用组65岁),而并用组的肿瘤范围、疾病分期及肿瘤直径均大于照射组。并用组的锁骨上窝或上腹部淋巴结转移13例,照
The 5-year survival rate of radiotherapy for esophageal cancer is 5% to 10%. From 1980 to 1992, the authors used radiotherapy for 81 cases of esophageal cancer that could not be surgically resected. Since 1986, 37 cases have been treated with platinum and radiation simultaneously. The administration method was: 9 cases were intravenously administered with cisplatin (CDDP) (50 mg once a week, total amount 200 mg); 11 cases were intravenously administered with carboplatin (CBDCA) (100-150 mg once a week, total amount) 400-900 mg); 17 patients received cisplatin arterial infusion (100 mg, interval 3 to 4 weeks, total 100 to 300 mg). The authors conducted a retrospective study of 37 cases of platinum combined with radiation therapy group (combined group) and 44 cases of radiation alone treatment group (irradiation group). The age of the group was younger than that of the irradiation group (mean age: 72 years in the irradiation group and 65 years in the group), while the tumor range, disease stage, and tumor diameter in the combined group were all greater than those in the irradiation group. The group used supraclavicular fossa or upper abdominal lymph node metastases in 13 cases.